Will GoodRX Stock Bounce Back?
GoodRX (NASDAQ:GDRX) tracks prescription drug prices and its model was…
Sell
44
ACIU Quote, Financials, Valuation and Earnings
Last price:
$2.08
Seasonality move
:
-14.27%
Day range:
$2.05 - $2.15
52-week range:
$1.43 - $4.26
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
6.36x
P/B ratio:
1.94x
Volume:
163.4K
Avg. volume:
130.2K
1-year change:
-42.5%
Market cap:
$208.2M
Revenue:
$31M
EPS (TTM):
-$0.59
Analysts' Opinion
-
Consensus RatingAC Immune SA has received a consensus rating of Buy. The company's average rating is a Buy based on 3 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $9.46, AC Immune SA has an estimated upside of 356.88% from its current price of $2.07.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $8.01 representing 100% downside risk from its current price of $2.07.
Fair Value
-
According to the consensus of 3 analysts, AC Immune SA has 356.88% upside to fair value with a price target of $9.46 per share.
ACIU vs. S&P 500
-
Over the past 5 trading days, AC Immune SA has underperformed the S&P 500 by -2.48% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
AC Immune SA does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
AC Immune SA revenues have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter AC Immune SA reported revenues of $1.1M.
Earnings Growth
-
AC Immune SA has grown year-over-year earnings for 0 quarters straight. In the most recent quarter AC Immune SA reported earnings per share of -$0.21.
Enterprise value:
43M
EV / Invested capital:
--
Price / LTM sales:
6.36x
EV / EBIT:
--
EV / Revenue:
1.32x
PEG ratio (5yr expected):
--
EV / Free cash flow:
0.83x
Price / Operating cash flow:
3.99x
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
-23.46%
Net Income Margin (TTM):
-177.6%
Return On Equity:
-42.34%
Return On Invested Capital:
-42.34%
Operating Margin:
-1956.57%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Income Statement | ||||||
| Revenue | -- | -- | $32.6M | -- | $1.1M | |
| Gross Profit | -- | -- | -- | -- | -- | |
| Operating Income | -$72.9M | -$63.4M | -$57.5M | -$23M | -$21.5M | |
| EBITDA | -$70M | -$59M | -$55.3M | -$19.8M | -$20.4M | |
| Diluted EPS | -$0.87 | -$0.69 | -$0.59 | -$0.21 | -$0.21 | |
| Period Ending | 2021-03-31 | 2022-03-31 | 2023-03-31 | 2024-03-31 | 2025-03-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $234.1M | $191.8M | $122.3M | $121.8M | $172.7M | |
| Total Assets | $242M | $255.1M | $185.2M | $185.4M | $239.6M | |
| Current Liabilities | $11.8M | $12.9M | $11.8M | $15.7M | $112.7M | |
| Total Liabilities | $21.8M | $23.2M | $17.8M | $25M | $132M | |
| Total Equity | $220.2M | $231.9M | $167.4M | $160.4M | $107.6M | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$70.2M | -$48M | $52.7M | $1.2M | -$20.9M | |
| Cash From Investing | $71.7M | -$67.4K | -$89.3M | -$27M | $3.4M | |
| Cash From Financing | -$571.9K | $47.5M | -$772.1K | -$787.2K | -$286.8K | |
| Free Cash Flow | -$71.2M | -$48.9M | $51.9M | $886.8K | -$21.3M | |
ACIU
Sector
Market Cap
$208.2M
$34.4M
Price % of 52-Week High
48.59%
48.88%
Dividend Yield
0%
0%
Shareholder Yield
-0.06%
-1.01%
1-Year Price Total Return
-42.5%
-37.36%
Beta (5-Year)
1.618
0.614
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$2.07
200-day SMA
Sell
Level
$2.47
Bollinger Bands (100)
Buy
Level
1.61 - 2.23
Chaikin Money Flow
Sell
Level
-167.6M
20-day SMA
Buy
Level
$2.03
Relative Strength Index (RSI14)
Buy
Level
55.57
ADX Line
Buy
Level
12.29
Williams %R
Sell
Level
-19.0595
50-day SMA
Buy
Level
$1.87
MACD (12, 26)
Buy
Level
0.05
25-day Aroon Oscillator
Sell
Level
-52
On Balance Volume
Neutral
Level
190.6M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-1.2476)
Sell
CA Score
(Annual)
Level (-0.748)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (2)
Sell
Ohlson Score
Level (2.2798)
--
Piotroski F Score
(Annual)
Level (--)
--
Quality Ratio Score
Level (--)
Sell
Fundamental Score
Level (3)
Revenue Forecast
Earnings per Share Forecast
Company Profile
AC Immune SA is a clinical-stage biopharmaceutical company that focuses on neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The Company has one segment. The Company currently focuses most of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.
Stock Forecast FAQ
In the current month, ACIU has received 3 Buy ratings 0 Hold ratings, and 0 Sell ratings. The ACIU average analyst price target in the past 3 months is $9.46.
-
Where Will AC Immune SA Stock Be In 1 Year?
According to analysts, the consensus estimate is that AC Immune SA share price will rise to $9.46 per share over the next 12 months.
-
What Do Analysts Say About AC Immune SA?
Analysts are divided on their view about AC Immune SA share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that AC Immune SA is a Sell and believe this share price will drop from its current level to $8.01.
-
What Is AC Immune SA's Price Target?
The price target for AC Immune SA over the next 1-year time period is forecast to be $9.46 according to 3 Wall Street analysts, 3 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is ACIU A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for AC Immune SA is a Buy. 3 of 3 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of ACIU?
You can purchase shares of AC Immune SA via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase AC Immune SA shares.
-
What Is The AC Immune SA Share Price Today?
AC Immune SA was last trading at $2.08 per share. This represents the most recent stock quote for AC Immune SA. Yesterday, AC Immune SA closed at $2.07 per share.
-
How To Buy AC Immune SA Stock Online?
In order to purchase AC Immune SA stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will FCX Benefit From Tariffs?
Freeport-McMoRan (NYSE:FCX) is among the world’s largest producers of copper…
Can Levi Stock Double?
Levi Strauss (NYSE:LEVI) is among the oldest clothing brands in…
Stock Ideas
Buy
71
Is NVDA Stock a Buy?
Market Cap: $4.2T
P/E Ratio: 58x
Buy
51
Is MSFT Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 43x
Sell
40
Is AAPL Stock a Buy?
Market Cap: $3.1T
P/E Ratio: 35x
Alerts
Buy
82
SBET alert for Jul 17
SharpLink Gaming [SBET] is down 2.6% over the past day.
Buy
93
EXOD alert for Jul 18
Exodus Movement [EXOD] is down 4.14% over the past day.
Buy
60
U alert for Jul 17
Unity Software [U] is up 7.51% over the past day.
